mitoxantrone has been researched along with Digestive System Neoplasms in 3 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Digestive System Neoplasms: Tumors or cancer of the DIGESTIVE SYSTEM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer." | 9.08 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. ( Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G, 1995) |
| "The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer." | 5.08 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. ( Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G, 1995) |
| " Fifty-five breast cancer patients treated with mitoxantrone, methotrexate and 5-fluorouracil gave a response rate of 52." | 5.06 | [Mitoxantrone containing multi-drug chemotherapy in the management of malignancies. Collaborative Group for Clinical Trial of Mitoxantrone]. ( , 1989) |
| "The relative increased risk of breast cancer in MS women under IS treatment warrants further attention." | 1.35 | Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lebrun, C | 1 |
| Debouverie, M | 1 |
| Vermersch, P | 1 |
| Clavelou, P | 1 |
| Rumbach, L | 1 |
| de Seze, J | 1 |
| Wiertlevski, S | 1 |
| Defer, G | 1 |
| Gout, O | 1 |
| Berthier, F | 1 |
| Danzon, A | 1 |
| Hausmaninger, H | 1 |
| Lehnert, M | 1 |
| Steger, G | 1 |
| Sevelda, P | 1 |
| Tschurtschenthaler, G | 1 |
| Hehenwarter, W | 1 |
| Fridrik, M | 1 |
| Samonigg, H | 1 |
| Schiller, L | 1 |
| Manfreda, D | 1 |
2 trials available for mitoxantrone and Digestive System Neoplasms
| Article | Year |
|---|---|
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diges | 1995 |
[Mitoxantrone containing multi-drug chemotherapy in the management of malignancies. Collaborative Group for Clinical Trial of Mitoxantrone].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Digestive System Neoplasms; | 1989 |
1 other study available for mitoxantrone and Digestive System Neoplasms
| Article | Year |
|---|---|
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Topics: Adult; Azathioprine; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Digestive | 2008 |